Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration

Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S. Heier, Sergio Leal, Frank G. Holz, William Lloyd Clark, David Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, Thomas Schmelter, Ursula Schmidt-Ott, Xin Zhang, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Rafia Bhore, Yenchieh Cheng, Tien Y. Wong

Open source

DOI: 10.1177/25158414251356388
Published: 8
Container: Therapeutic Advances in Ophthalmology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1177/25158414251356388,
  title = {Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration},
  author = {Paolo Lanzetta and Jean-François Korobelnik and Jeffrey S. Heier and Sergio Leal and Frank G. Holz and William Lloyd Clark and David Eichenbaum and Tomohiro Iida and Xiaodong Sun and Alyson J. Berliner and Andrea Schulze and Thomas Schmelter and Ursula Schmidt-Ott and Xin Zhang and Robert Vitti and Karen W. Chu and Kimberly Reed and Rohini Rao and Rafia Bhore and Yenchieh Cheng and Tien Y. Wong},
  year = {2025},
  journal = {Therapeutic Advances in Ophthalmology},
  doi = {10.1177/25158414251356388},
  url = {https://doi.org/10.1177/25158414251356388}
}

RIS

TY  - JOUR
TI  - Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration
AU  - Paolo Lanzetta
AU  - Jean-François Korobelnik
AU  - Jeffrey S. Heier
AU  - Sergio Leal
AU  - Frank G. Holz
AU  - William Lloyd Clark
AU  - David Eichenbaum
AU  - Tomohiro Iida
AU  - Xiaodong Sun
AU  - Alyson J. Berliner
AU  - Andrea Schulze
AU  - Thomas Schmelter
AU  - Ursula Schmidt-Ott
AU  - Xin Zhang
AU  - Robert Vitti
AU  - Karen W. Chu
AU  - Kimberly Reed
AU  - Rohini Rao
AU  - Rafia Bhore
AU  - Yenchieh Cheng
AU  - Tien Y. Wong
PY  - 2025
JO  - Therapeutic Advances in Ophthalmology
DO  - 10.1177/25158414251356388
UR  - https://doi.org/10.1177/25158414251356388
ER  -

APA

Lanzetta, P., Korobelnik, J., Heier, J. S., Leal, S., Holz, F. G., Clark, W. L., Eichenbaum, D., Iida, T., Sun, X., Berliner, A. J., Schulze, A., Schmelter, T., Schmidt-Ott, U., Zhang, X., Vitti, R., Chu, K. W., Reed, K., Rao, R., Bhore, R., Cheng, Y., & Wong, T. Y. (2025). Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration. Therapeutic Advances in Ophthalmology. https://doi.org/10.1177/25158414251356388

Source records

doaj · retrieved 2026-09-25T17:27:21.123Z